Pfizer and Amgen fight to avoid patent cliff falls in multi-billion dollar buying sprees
With significant revenue drop-offs from existing branded products set to decline steeply in the second half of this decade, major portfolio acquisitions are a priority for both companies
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.